Taking people in United StatesNo phase

Studying why some people with atopic dermatitis have more severe disease

Studies people with atopic dermatitis who carry the IL-4Ra R576 gene variant.

Key facts

Who runs it: Boston Children's Hospital
Where: Boston, United StatesSee the site
Trial code: NCT04455906
Registry title: Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
Status: Recruiting
People taking part: 111 people, planned
Started: 30 Nov 2020
Expected to end: 15 Sept 2027
Type of study: Observational
Record updated: 18 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with atopic dermatitis (eczema) to study whether the IL-4Ra R576 gene variant is linked to more active disease.

Age: 6 to 65 years
Sex: Men and women
Disease stage: Atopic dermatitis that meets the standard diagnostic criteria for AD.
Earlier treatment: Cannot have used these recently: systemic immune-suppressing drugs within 4 weeks, phototherapy within 4 weeks, biologics within sixteen weeks, topical steroids, topical calcineurin inhibitors or crisaborale within 7 days, bleach baths within 7 days, oral or topical antibiotics within 21 days.
Biomarker or test result: The record names the IL-4Ra R576 polymorphism as the focus of the study but does not state a test result needed to join.

Main reasons for not taking part

Enrolled in another clinical trial
Hypersensitivity to an agent used for the skin decolonization protocol
History of HIV, hepatitis B, hepatitis C, tuberculosis or malignancy
Skin conditions that may interfere with assessments, such as psoriasis or cutaneous T cell lymphoma
Severe ongoing medical illness, fever at the visits, or suspected immune deficiency

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

Male or female participants ≥6 to 65 yrs of age
Meet AD Standard Diagnostic Criteria

Who cannot take part

Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate)
Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks
Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days
Asthmatics receiving more than 500 μg per day of inhaled corticosteroids
Hypersensitivity to an agent used for the skin decolonization protocol
History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy
Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease
Febrile illness at time of visits
Suspected immune deficiency or family history of primary immunodeficiency
Enrollment in another clinical trial
Phototherapy for AD within 4 weeks
Bleach baths within 7 days of the first Visit
Use of oral or topical antibiotics within 21 days of the beginning of the study
Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 6 and 65 years old?

Where in United States

Boston Children's HospitalBoston, United StatesContact: Amparito CunninghamTaking people

About the trial

What the trial wants to find out

This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.